Truncal Acne and Scarring: A Comprehensive Review of Current Medical and Cosmetic Approaches to Treatment and Patient Management
- PMID: 36539678
- DOI: 10.1007/s40257-022-00746-4
Truncal Acne and Scarring: A Comprehensive Review of Current Medical and Cosmetic Approaches to Treatment and Patient Management
Abstract
Acne vulgaris is one of the most common skin disorders worldwide. It typically affects skin areas with a high density of sebaceous glands such as the face, upper arms, chest, and/or back. Historically, the majority of research efforts have focused on facial acne vulgaris, even though approximately half of patients with facial lesions demonstrate truncal involvement. Truncal acne vulgaris is challenging to treat and poses a significant psychosocial burden on patients. Despite these characteristics, studies specifically examining truncal acne vulgaris are limited, with treatment guidelines largely derived from facial protocols. Therefore, truncal acne remains an understudied clinical problem. Here, we provide a clinically focused review on the epidemiology, evaluation, and available treatment options for truncal acne vulgaris. In doing so, we highlight knowledge gaps with the goal of spurring further investigation into the management of truncal acne vulgaris.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Similar articles
-
Truncal Acne: A Neglected Entity.J Drugs Dermatol. 2019 Dec 1;18(12):205-1208. J Drugs Dermatol. 2019. PMID: 31859617
-
A closer look at truncal acne vulgaris: prevalence, severity, and clinical significance.J Drugs Dermatol. 2007 Jun;6(6):597-600. J Drugs Dermatol. 2007. PMID: 17668525
-
Truncal acne, what do we know?J Eur Acad Dermatol Venereol. 2020 Oct;34(10):2241-2246. doi: 10.1111/jdv.16634. Epub 2020 Jun 8. J Eur Acad Dermatol Venereol. 2020. PMID: 32421879 Review.
-
SUPPLEMENT INDIVIDUAL ARTICLES: Update on Truncal Acne: A Review of Treatments for a Neglected Disease and the Re-Emergence of Tazarotene.J Drugs Dermatol. 2022 Dec 1;21(12):SF3446185-SF34461814. J Drugs Dermatol. 2022. PMID: 36468963 Review.
-
Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne.J Am Acad Dermatol. 2019 Jun;80(6):1691-1699. doi: 10.1016/j.jaad.2019.02.044. Epub 2019 Feb 22. J Am Acad Dermatol. 2019. PMID: 30802558 Clinical Trial.
Cited by
-
Case report: Acne vulgaris treatment with 5-Aminolaevulinic acid photodynamic therapy and adalimumab: a novel approach.Front Med (Lausanne). 2023 May 12;10:1187186. doi: 10.3389/fmed.2023.1187186. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37250640 Free PMC article.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical